PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

Author(s): COSTA Angela Aparecida, INENAMI Marta, JUAREZ Edmundo, LLACEN Pedro Dorlhiac, RAW Isaias
Keywords: Recombinant hepatitis B vaccine, Clinical trials, Adults
Journal: Revista do Instituto de Medicina Tropical de São Paulo
Year: 1997
Full text: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651997000100008
Publisher: Instituto de Medicina Tropical
Abstract: Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects)